Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00620
|
|||||
| Drug Name |
Pramipexole
|
|||||
| Synonyms |
(-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole; Mirapex; Mirapex (TN); Mirapexin (TN); Pramipexol; Pramipexole (USAN/INN); Pramipexole [USAN:INN]; Pramipexolum; SND-919; SUD919CL2Y; Sifrol(TN); U-98528E
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Parkinson's Disease [ICD11:8A00.0] | Approved | [1] | |||
| Therapeutic Class |
Antiparkinson Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H17N3S
|
|||||
| Canonical SMILES |
CCCNC1CCC2=C(C1)SC(=N2)N
|
|||||
| InChI |
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
|
|||||
| InChIKey |
FASDKYOPVNHBLU-ZETCQYMHSA-N
|
|||||
| CAS Number |
CAS 104632-26-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 211.33 | Topological Polar Surface Area | 79.2 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
1.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103245538
,104010405
,104408638
,10633207
,11342091
,11362274
,11364752
,11367314
,11369876
,11378041
,11487676
,11495652
,118317775
,124658831
,124800011
,127818967
,131293470
,135017226
,135650847
,137055231
,137205527
,142970931
,144205998
,14748917
,14797724
,160831530
,162038142
,163094982
,163392621
,164216289
,26719739
,29300417
,46386856
,46505897
,47207239
,47589086
,48416455
,49681584
,49890661
,50112695
,56464131
,57309747
,57339564
,75921463
,7980372
,91615696
,92308251
,92309051
,93166408
,99431914
|
|||||
| ChEBI ID |
ChEBI:8356
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| 2-Oct | Transporter Info | Organic cation transporter 2 | Substrate | [3] | ||
| References | ||||||
| 1 | Pramipexole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82. | |||||
| 3 | Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.